Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. (NASDAQ: BHST) is a biotechnology company that describes itself as a leader in Botanical Synthesis, using its patented plant cell-based platform to grow active plant compounds without cultivating the whole plant. The BioHarvest news stream highlights how this technology underpins both its direct-to-consumer nutraceutical products and its contract development and manufacturing (CDMO) services.
Investors following BHST news can read about developments in the company’s VINIA brand, including capsules, hot beverages, daily chews, and VINIA Blood Flow Hydration, which the company presents as a hydration solution powered by the blood flow benefits of Piceid resveratrol. News items also cover subscriber trends, online channel performance, and the expansion of VINIA into broader health and wellness categories.
Another major theme in BioHarvest’s news is the evolution of its CDMO Services division. Company updates describe new customer contracts in pharmaceuticals, nutrition, fragrance, and nutraceuticals, such as a saffron-derived compound partnership with Saffron Tech and work on a plant-based fragrance compound. Releases also discuss milestones like producing plant-based exosomes at scale in a bioreactor and integrating AI-based tools into a second-generation Botanical Synthesis process.
Capital markets and regulatory announcements form a further part of the BHST news flow, including public offerings under a Form F-3 shelf registration, material change reports, and interim financial results filed on Form 6-K. Readers can use this page to monitor BioHarvest’s operational updates, technology progress, and financing activities in one place.
BioHarvest Sciences (NASDAQ: BHST), a pioneer in Botanical Synthesis technology, will release its Q1 2025 financial results on May 15, 2025, after market close. The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on the same day.
Management will discuss quarterly results, provide a corporate update, and hold a Q&A session. The conference call can be accessed via U.S./Canada dial-in (1-877-300-8521) or International dial-in (1-412-317-6026) using Conference ID 2552254. A telephone replay will be available through May 29, 2025.
BioHarvest Sciences (NASDAQ: BHST) reported strong Q4 2024 financial results with revenues growing 62% to $7.3 million, exceeding guidance. Full-year 2024 revenues increased 99% to $25.2 million with gross margins expanding 1,000 basis points to 55%.
Key highlights include a CDMO partnership with Tate & Lyle for plant-based sweeteners development, successful Nasdaq Global Market uplisting, and VINIA® subscribers surpassing 50,000. The company launched VINIA® SuperFood tea line following successful coffee line introduction which generated $2.3 million since December 2023.
Q4 gross profit increased 80% to $4.1 million (56.7% margin), while marketing expenses decreased to 40.4% of revenue. Management projects Q1 2025 revenues of at least $7.8 million and expects adjusted EBITDA breakeven in H2 2025. The company ended Q4 with $2.4 million cash, subsequently raising $3.9 million in debt financing.
BioHarvest Sciences (NASDAQ: BHST) has scheduled its Q4 and full year 2024 earnings release for March 31, 2025, after market close. The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on the same day.
The earnings call will include a discussion of financial results, corporate updates, and a Q&A session. Participants can join using U.S./Canada dial-in (1-844-825-9789) or International dial-in (1-412-317-5180) with Conference ID 10197712. A replay will be available through April 14, 2025, using pin number 10197712.
BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors throughout the event.
The company, which pioneers the patented Botanical Synthesis technology platform, views this as a significant opportunity to showcase its growth trajectory. Following their Nasdaq listing and the launch of their CDMO Services Division, BioHarvest has achieved notable milestones, including:
- VINIA product reaching $50 Million in cumulative sales
- Advancement in CDMO Services division research for plant-based solutions
- Partnerships with pharmaceutical, nutraceutical, cosmetics, and nutrition sectors
BioHarvest Sciences (NASDAQ: BHST) has announced promising in vitro test results for their proprietary Olive Cell compound, showing reduced fat accumulation in human liver cells. The compound, rich in Verbascoside, demonstrated effectiveness in mitigating fat accumulation in liver steatosis and fibrosis models.
The development targets Non-Alcoholic Fatty Liver Disease (NAFLD), which affects 30-40% of U.S. adults, with its severe form NASH impacting 3-5% of the adult population. The company plans to launch the Olive Cell product as a nutraceutical in 2026, while exploring pharmaceutical partnerships.
The tests, conducted on human hepatic cells, showed the compound's ability to reduce collagen type 1 levels in XL-2 cells. This product will join VINIA® in BioHarvest's portfolio, which has already achieved over $50M USD in sales with 50,000+ active subscribers.
BioHarvest Sciences (NASDAQ: BHST) announced that sales of its flagship product VINIA, a red grape cell-based supplement, have exceeded $50 million USD in cumulative sales. The majority of these sales occurred since the US launch less than 4 years ago.
The company has achieved over 50,000 active U.S. users on recurring subscription packages, with VINIA receiving approximately 8,000 customer reviews and a verified rating of 4.8/5. Clinical trials have demonstrated VINIA's ability to improve blood flow and arterial dilation.
To support future growth, BioHarvest plans to expand its production capacity by 4x with a new 100-ton per year facility, expected to be operational in late 2026. The company has invested 15 years and over $100M in developing its patented Botanical Synthesis technology, which is now being used in their CDMO Services division for pharmaceutical and nutrition industry partners.
BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the upcoming WeBull Consumer Stocks Virtual Webinar on February 18, 2025, at 2:00 p.m. Eastern time. CEO Ilan Sobel will present the company's investor story, focusing on their patented Botanical Synthesis technology platform.
The presentation will showcase BioHarvest's approach to developing and commercializing plant-based compounds, highlighting the growth of their direct-to-consumer business, including the VINIA® product line, and their CDMO Services business unit. The company aims to demonstrate how their technology impacts various industries, including Nutraceuticals, Pharmaceuticals, Cosmeceuticals, and Nutrition, through the delivery of consistent, economically viable, and patentable plant compounds.
The webinar requires mandatory pre-registration, and a replay link will be available on BioHarvest's investor relations website following the event.
BioHarvest Sciences (NASDAQ: BHST) has appointed Sharon Malka as an independent director, effective immediately. Malka brings over 25 years of financial and capital markets experience to the board. He currently serves as CEO of Dotz Nano and is on the board of MediWound , where he previously held positions as CFO and CEO.
Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division, highlighted Malka's operational experience in advancing innovative technologies and structuring strategic transactions as valuable assets for the company's growth. Malka, a certified CPA with an MBA and Harvard Business School Executive Education, expressed enthusiasm about contributing to BioHarvest's development of science-based therapeutic solutions using its Botanical Synthesis technology.
BioHarvest Sciences (NASDAQ: BHST) released a shareholder letter highlighting key achievements in 2024 and outlook for 2025. The company introduced its new CDMO Services division, partnering with Tate & Lyle for sweetener development. The VINIA® capsule business doubled, with approximately 50,000 active U.S. subscribers and a Q4 2024 run rate of nearly $30 million.
Key developments include the launch of VINIA® Functional Superfood Coffee line, generating $1.6 million in sales since launch, and the acquisition of an 80,000 square foot corporate campus in Yavneh, Israel. Gross margins improved from 44% in Q3 2023 to 56% in Q3 2024, with expectations to exceed 60% in 2025. The company successfully uplisted to Nasdaq and targets adjusted EBITDA profitability in H2 2025.
Tate & Lyle and BioHarvest Sciences (NASDAQ: BHST) have announced a strategic partnership to develop next-generation plant-based ingredients for healthier food and beverages. The collaboration will initially focus on developing botanical sweetening ingredients using BioHarvest's proprietary Botanical Synthesis platform, which produces non-GMO plant-derived ingredients by growing targeted plant cells that mirror and magnify phyto-nutrients without traditional farming.
The partnership aims to create sugar-like sweeteners without aftertaste while using significantly less land and water compared to traditional methods. Tate & Lyle will contribute its sugar reduction expertise, regulatory knowledge, and global customer access, while BioHarvest brings its validated industrial-scale plant cell technology. The collaboration is part of Tate & Lyle's open innovation program to create cutting-edge solutions for the food and beverage industry.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
